ADMA:NSD-ADMA Biologics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.17

Change

-0.01 (-0.46)%

Market Cap

USD 0.19B

Volume

1.49M

Average Target Price

USD 7.00 (+222.58%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing ADMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.75% 17% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.75% 17% F 13% F
Trailing 12 Months  
Capital Gain -51.24% 14% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.24% 14% F 9% F
Trailing 5 Years  
Capital Gain -74.04% 32% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.04% 32% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -8.92% N/A N/A 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.92% N/A N/A 19% F
Risk Return Profile  
Volatility (Standard Deviation) 42.12% N/A N/A 29% F
Risk Adjusted Return -21.18% N/A N/A 23% F
Market Capitalization 0.19B 41% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.29 72% C- 47% F
Price / Cash Flow Ratio -2.47 29% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -99.24% 31% F 13% F
Return on Invested Capital -57.75% 56% F 17% F
Return on Assets -18.96% 71% C- 20% F
Debt to Equity Ratio 260.72% 9% F 7% F
Technical Ratios  
Short Ratio 1.36 69% D+ 70% C-
Short Percent 21.18% 8% F 10% F
Beta 1.98 27% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector